C12N 2760/16132
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2760/16132 (Use of virus as therapeutic agent, other than vaccine) appears on 22 US grants and 37 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 37
- Assignees
- 26
- Inventors
- 64
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 2 | 1 |
| 2004 | 0 | 1 |
| 2005 | 2 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 2 | 2 |
| 2010 | 0 | 3 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 2 | 3 |
| 2015 | 1 | 0 |
| 2016 | 2 | 3 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 1 | 5 |
| 2020 | 0 | 2 |
| 2021 | 0 | 2 |
| 2022 | 2 | 5 |
| 2023 | 2 | 2 |
| 2024 | 1 | 3 |
| 2025 | 1 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Nucleic acid molecules and dual-functional peptides having antiviral activity and delivery activity, compositions and methods thereof12 May 2026US 12,624,368 B2The University of Hong Kong
- Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same23 Sep 2025US 12,419,946 B2Duke University
- Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer31 Dec 2024US 12,178,869 B2Codagenix Inc.
- Method for the separation of virus compositions including depletion and purification thereof11 Jul 2023US 11,697,800 B2MAX-PLANCK-GESELLSCHAFT zur FOERDERUNG der WISSENSCHAFTEN.e.V
- Pharmaceutical composition comprising nanoperforator for preventing or treating viral infectious diseases3 Jan 2023US 11,541,100 B2Mvrix Co., Ltd.
- Non-toxic destruction of cancer cells using viral vectored injections20 Nov 2025US 2025/0352628 A1
- Influenza virus defective interfering particles for use in the prophylactic or therapeutic treatment of coronaviridae infection11 Jul 2024US 2024/0226204 A9Helmholtz-Zentrum FüR Infektionsforschung GmbH
- Cryptic proteins expressed from defective viral genomes interfere with influenza virus replication11 Jul 2024US 2024/0228980 A1Wisconsin Alumni Research Foundation
- Influenza virus defective interfering particles for use in the prophylactic or therapeutic treatment of coronaviridae infection25 Apr 2024US 2024/0131094 A1Helmholtz-Zentrum FüR Infektionsforschung GmbH
- Nucleic acid construct, recombinant influenza virus, method for preparing a recombinant influenza virus, composition and use19 Oct 2023US 2023/0332174 A1FundaçãO Oswaldo Cruz
Most cited
By later US patents
- Interferon inducing genetically engineered attenuated viruses39US 6,468,544 B1Mount Sinai School of Medicine of the City University of New York · 2002
- Methods and interferon deficient substrates for the propagation of viruses37US 6,852,522 B1Mount Sinai School of Medicine of New York University · 2005
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals35US 6,669,943 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses34US 6,573,079 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses33US 7,494,808 B2Mount Sinai School of Medicine of New York University · 2009